This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

In Vivo Phosphorus 31 Magnetic Resonance Spectroscopy

Charles-André Cuénod, MD; David B. Kaplan, MS; Jean-Luc Michot, PhD; Philippe Jehenson, MD, PhD; Anne Leroy-Willig, MD, PhD; Françoise Forette, MD; André Syrota, MD, PhD; François Boiler, MD, PhD

Arch Neurol. 1995;52(1):89-94.

Abstract
Objective
To determine whether changes in phosphomonoester and phosphodiester levels could be detected in vivo with phosphorus magnetic resonance spectroscopy in the early stage of Alzheimer's disease (AD).

Design
Survey-type of case-control study using neuropsychological testing as criterion standard with blinded data analysis.

Setting
Patients were from a neurology clinic in Paris, France. The controls were from the community. Magnetic resonance measurements were performed in the prefrontal region of the brain with a clinical 1.5-T scanner. Blinded data analysis.

Participants
Twenty-four patients with mild AD and 15 age-matched healthy volunteers. Subjects were separated into two groups, both composed of patients with AD and healthy volunteers. Two successive acquisition protocols were used in the two groups.

Results
A significant increase in the phosphomonoester—total phosphorus ratio was found in patients with AD compared with controls. In this series, use of a ratio above 11% as a threshold to test our sample yielded an 83.3% sensitivity and a 73.3% specificity test for AD. Other metabolite ratios (inorganic phosphate, phosphodiesters, phosphocreatine, and nucleotide phosphates to total phosphorus) were not significantly different between patients and controls. No metabolite ratio correlated with the neuropsychological status as assessed by the Mini-Mental State Examination.

Conclusion
Changes in phospholipid metabolism can be detected in vivo in the early stage of AD. Discrepancies in the literature may be due to differences in technical setting or in subject population types.

Author Affiliations
From the Frédéric-Joliot Hospital, Atomic Energy Commission, Orsay (Drs Cuénod, Jehenson, Leroy-Willig, and Syrota and Mr Kaplan), Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 324, Paris (Drs Cuénod, Michot, Forette, and Boiler and Mr Kaplan), and Broca Hospital, Paris (Drs Forette and Boller), France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule
Bottiglieri
Am. J. Clin. Nutr. 2002;76 :1151S-1157S.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias
Hsu et al.
J Geriatr Psychiatry Neurol 2001;14:145-166.
ABSTRACT  

Brain Biochemistry Using Magnetic Resonance Spectroscopy: Relevance to Psychiatric Illness in the Elderly
Moore et al.
J Geriatr Psychiatry Neurol 1999;12:107-117.
ABSTRACT  

Proton Magnetic Resonance Spectroscopy of Vascular- and Alzheimer-Type Dementia
Kattapong et al.
Arch Neurol 1996;53:678-680.
ABSTRACT